B4GAT1: Beta-1,4-Glucuronyltransferase 1

Gene encoding a glycosyltransferase involved in dystroglycan O-mannosylation and congenital muscular dystrophy

Gene Information Card

Symbol B4GAT1
Full Name Beta-1,4-Glucuronyltransferase 1
Gene Type Protein coding
Chromosomal Location 11q13.2
NCBI Gene ID 11041 ncbi.nlm.nih.gov/gene/11041
Ensembl ID ENSG00000149294
UniProt ID Q9P2K5
OMIM ID 615287
HGNC ID 29579
Aliases B3GNT1, iGAT, MDDGA13, MDDGC13

Description

B4GAT1 encodes beta-1,4-glucuronyltransferase 1, a Golgi-resident enzyme that catalyzes the transfer of glucuronic acid (GlcA) to O-mannosyl glycans on alpha-dystroglycan. This modification is essential for the binding of extracellular matrix proteins such as laminin. Mutations in B4GAT1 cause a spectrum of muscular dystrophy-dystroglycanopathies, including congenital muscular dystrophy with brain and eye anomalies (MDDGA13) and limb-girdle muscular dystrophy (MDDGC13).

Disease Associations

Disease category Pathophysiological mechanism Genomic evidence
Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies) type A13 (MDDGA13) Loss-of-function mutations impair GlcA transfer, disrupting alpha-dystroglycan glycosylation and laminin binding, leading to severe neurodevelopmental and muscular defects. OMIM #615287; ClinVar
Muscular dystrophy-dystroglycanopathy (limb-girdle) type C13 (MDDGC13) Hypomorphic variants reduce enzyme activity, causing milder, later-onset muscular dystrophy without significant brain involvement. OMIM #615287; ClinVar
Walker-Warburg syndrome (WWS) Biallelic loss-of-function mutations in B4GAT1 are associated with WWS, a severe form of congenital muscular dystrophy with cobblestone lissencephaly and eye malformations. OMIM #615287; NCBI GeneReviews

Expression Profile

Tissue Expression
Tissue nTPM level
Brain 12.5 Medium
Heart 8.2 Low
Skeletal Muscle 15.3 Medium
Liver 6.1 Low
Kidney 9.8 Low
Lung 7.4 Low
Placenta 11.0 Medium
Cell Line Expression
Cell Line nTPM Notes
HEK 293 18.5 Moderate expression
HeLa 14.2 Moderate expression
HepG2 9.1 Low expression
K562 6.8 Low expression
SH-SY5Y 20.3 Moderate expression
Data source:Human Protein Atlas(proteinatlas.org)

Mutations & Variants

Hotspot Mutations
Variant Type Frequency Functional Description
c.1A>G (p.Met1?) Missense (start loss) Rare Loss of translation initiation; complete loss of function
c.512G>A (p.Arg171His) Missense Rare Reduced enzymatic activity; associated with MDDGC13
c.679C>T (p.Arg227*) Nonsense Rare Premature stop; loss of function; associated with MDDGA13
c.1000C>T (p.Arg334Trp) Missense Rare Impaired glucuronyltransferase activity; pathogenic
Mutation functional classification

Loss of Function (LOF)

Most pathogenic mutations (nonsense, frameshift, start loss) lead to complete or severe loss of enzyme activity, causing severe congenital muscular dystrophy (MDDGA13).

Gain of Function (GOF)

No gain-of-function mutations have been reported for B4GAT1.

Dominant Negative (DN)

No dominant-negative mechanisms have been described; all reported pathogenic variants are recessive.

Pathways

O-mannosyl glycan biosynthesis (Reactome: R-HSA-5173105)
Dystroglycan O-mannosylation (KEGG: hsa00514 – Other types of O-glycan biosynthesis)

Protein Summary

Beta-1,4-glucuronyltransferase 1 (B4GAT1) is a 334-amino acid type II transmembrane protein localized to the Golgi apparatus. It catalyzes the addition of glucuronic acid (GlcA) in a beta-1,4 linkage to O-mannose glycans on alpha-dystroglycan. This modification is critical for the formation of the laminin-binding glycan epitope. The enzyme requires manganese as a cofactor and is part of the glycosyltransferase family 49 (GT49).

Related Products

Product name Cat.No. Species Gene ID
B4GAT1 Knockout HEK293 Cell Line EDJ-KQ7256 Human 11041 Details Get a Quote
B4GAT1 Knockout A-549 Cell Line EDJ-KQ32258 Human 11041 Details Get a Quote
B4GAT1 Knockout HCT 116 Cell Line EDJ-KQ32259 Human 11041 Details Get a Quote
B4GAT1 Knockout HeLa Cell Line EDJ-KQ32260 Human 11041 Details Get a Quote
Displaying Records 1 To 4 Of 4 Records
Contact Us
*
*
*
*
How did you hear about us: